Efficacy and safety of ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis: Subgroup analysis of a placebo‐controlled, phase 3 study (UNCOVER‐1)

The present study describes a subgroup analysis of 33 Japanese patients participating in UNCOVER‐1, an international, placebo‐controlled, phase 3 study of ixekizumab in patients with moderate‐to‐severe psoriasis. Patients were randomized to a placebo (n = 13) or ixekizumab 80 mg every 4 (IXEQ4W, n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Imafuku, Shinichi, Torisu‐Itakura, Hitoe, Nishikawa, Atsushi, Zhao, Fangyi, Cameron, Gregory S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Concise Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697664/
https://www.ncbi.nlm.nih.gov/pubmed/28635026
http://dx.doi.org/10.1111/1346-8138.13927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697664/
https://www.ncbi.nlm.nih.gov/pubmed/28635026
http://dx.doi.org/10.1111/1346-8138.13927

Ejemplares similares